Navigation Links
Sygnis Pharma AG announces date for presentation of clinical,results

HEIDELBERG, Germany, 11 July 2007 – On 23 July SYGNIS Pharma AG will present the results of the clinical phase IIa study for AX200 (AXIS-study).

AX200, a compound for the treatment of stroke, is the most advanced drug candidate in SYGNIS’ product pipeline. The primary aim of the study is to show safety and tolerability of AX200 in acute stroke patients. The results of the AXIS-study are expected to provide information for the further clinical development of AX200.

Furthermore, the company announces that this year’s Annual General Meeting will take place on 28 November 2007 in Eppelheim.

About SYGNIS Pharma

SYGNIS Pharma AG, with head offices in Heidelberg, is a specialist pharmaceutical company listed on the Prime Standard of the German stock exchange. The company is focusing on the research, development and marketing of innovative therapies for the treatment of neurodegenerative diseases. These include stroke, Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease or neurological disorders resulting from injury, such as trauma of the brain or spinal cord. All these disorders are characterised by the fact that, as the disease progresses, nerve cells die off. Although there is a great medical demand, there are currently no or only inadequate treatment options available.

In its drug development, the company has taken a completely novel approach: it develops compounds that protect nerve cells in the acute phase of the disease, and beyond that, also stimulate the regeneration of the damaged nervous system.

For more information, please contact:

Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812 franz-werner.haas@sygnis.de

### Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as f
'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sygnis Pharma announces date for presentation clinical results
(Date:5/17/2013)... , May 17, 2013  Boston Scientific Corporation (NYSE: ... the annual EuroPCR Scientific Program May 21-24 in ... to present a particularly rich and diversified set of ... Dawkins , M.D., global chief medical officer, Boston ... be presented, including the NG PROMUS trial, which evaluated ...
(Date:5/16/2013)... , May 16, 2013  Nektar Therapeutics, (Nasdaq: ... W. Robin , is scheduled to present at the ... York at the Sheraton New York Hotel on ... The presentation will be accessible via a Webcast through ... of the Nektar website: http://www.nektar.com . This Webcast will ...
(Date:5/16/2013)... , May 16, 2013  Amgen (NASDAQ: ... Conference on Tuesday, May 21, 2013, at the Sheraton New ... , beginning at 10:00 a.m. Eastern Daylight Time. ... of Research and Development at Amgen, will present at the ... the Events Calendar on Amgen,s website, www.amgen.com , under ...
Breaking Medicine Technology:Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... Mass., Jan. 5, 2011 Avaxia Biologics, Inc., ... technology to deliver orally-active antibodies to the gastrointestinal ... pre-clinical data in animal models of inflammatory bowel ... significantly reduced disease severity in three different animal ...
... Transposagen Biopharmaceuticals, Inc. (Transposagen), a leader ... entered into a non-exclusive license agreement with Cellular ... human induced pluripotent stem (iPS) cell lines and tissue ... The license agreement allows CDI to use Transposagen,s ...
Cached Medicine Technology:Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011 2Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells 2Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells 3
(Date:5/20/2013)... 2013 The transvaginal mesh lawyers at ... firm, report that two important bellwether trials are set ... and federal litigations established for C.R. Bard transvaginal ... C.R. Bard bellwether trial will begin in the federal ... Virginia. (In re: C.R. Bard, Inc., Pelvic Repair ...
(Date:5/20/2013)... Townsend Security, a leading authority in ... Alliance Key Manager hardware security module (HSM) will ... for TrueCrypt for Windows . Enterprises can now ... TrueCrypt for data protection. , “Townsend Security is ... for TrueCrypt encryption. Today's announcement reflects our strong ...
(Date:5/20/2013)... 2013 Gerald Wojtala, executive director of ... at North Carolina Food Safety and Defense Task Force’s ... Need for Partnerships – from Farm to Fork – ... for May 22-23 at the Sheraton Imperial Hotel, will ... sector have in protecting the food supply. , Wojtala ...
(Date:5/19/2013)... 20, 2013 California has one of the ... employers are quickly discovering that comprehensive background checks are playing ... job. Driving records can paint an accurate ... that person has any DUI arrests, speeding offenses, and traffic ... are lining up to experience 4SafeDrivers.com, a new online service ...
(Date:5/19/2013)... Due to the extremely high return on ... decided to invite bloggers and business owners in this ... , Businesses in the Mesothelioma sector have recently had ... with ad networks. , Thousands of people are ... are unsure where to turn. By using MileageAds ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 2Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 4Health News:Alliance Key Manager, Townsend Security’s FIPS 140-2 Compliant Encryption Key Manager Now Includes Support for Managing TrueCrypt Passwords 2Health News:Alliance Key Manager, Townsend Security’s FIPS 140-2 Compliant Encryption Key Manager Now Includes Support for Managing TrueCrypt Passwords 3Health News:IFPTI Executive Director to Speak at North Carolina Food Safety and Defense Task Force Annual Conference 2Health News:4SafeDrivers.com Announces Driving Record Searches for California Employers 2Health News:Mileageads Ad Network Now Invites Bloggers and Business Owners in Mesothelioma Sector to Advertise on Their Ad Network 2
... can deliver organized follow-up care for depression effectively and ... Group Health patients that the Journal of General ... After five months, compared to the half of ... half who had three online care management contacts with ...
... WEDNESDAY, March 16 (HealthDay News) -- Newly proposed national ... from power plants could prevent as many as 17,000 ... to the U.S. Environmental Protection Agency. The proposed ... a court deadline, could also prevent 120,000 cases of ...
... French . , Toronto (March 16, 2011) ... received $16 million in funding. The studies, co-funded by the ... Agency (CSA), were announced today at the University of Toronto ... Jane Aubin, Scientific Director of the Canadian Institutes of Health ...
... HealthDay Reporter , TUESDAY, March 15 (HealthDay ... chatting on cell phones while crossing the street, because ... age group than for college students. In laboratory ... aged 59 to 81 and 18 undergraduates aged 18 ...
... 2011 -- Children and adolescents growing up with inflammatory bowel ... study by researchers at McMaster University and the McMaster Children,s ... Pediatrics online, shows children and youth with the most ... 25 per cent lower than other children their age, and ...
... , TUESDAY, March 15 (HealthDay News) -- The cholera ... the 400,000 cases predicted by the United Nations, new study ... cases of the potentially deadly diarrheal disease -- an estimated ... to researchers at the University of California, San Francisco and ...
Cached Medicine News:Health News:Online messaging delivers follow-up care for depression 2Health News:EPA Proposes Tougher Air Pollution Rules for Power Plants 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 3Health News:Crossing Street While on Cell Phone Risky for Seniors 2Health News:Youth with IBD are less fit than their peers: McMaster study 2Health News:Haiti Cholera Epidemic Could Sicken 779,000 This Year 2
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
Maximum contact. Minimum wear. Outstanding results....
... knee prosthesis stems from many years of ... manufacturing technologies have been used in order ... as a favorable pressure distribution pattern on ... to a minimum. The inherent design of ...
...
Medicine Products: